1. Home
  2. ALKT vs NTLA Comparison

ALKT vs NTLA Comparison

Compare ALKT & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alkami Technology Inc.

ALKT

Alkami Technology Inc.

HOLD

Current Price

$18.95

Market Cap

1.8B

Sector

Technology

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$13.82

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALKT
NTLA
Founded
2007
2014
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.5B
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
ALKT
NTLA
Price
$18.95
$13.82
Analyst Decision
Buy
Buy
Analyst Count
7
23
Target Price
$28.57
$20.02
AVG Volume (30 Days)
1.5M
5.4M
Earning Date
04-29-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
27.43
EPS
N/A
N/A
Revenue
$152,159,000.00
$67,671,000.00
Revenue This Year
$21.85
N/A
Revenue Next Year
$16.90
$62.75
P/E Ratio
N/A
N/A
Revenue Growth
35.68
16.92
52 Week Low
$14.11
$6.98
52 Week High
$31.18
$28.24

Technical Indicators

Market Signals
Indicator
ALKT
NTLA
Relative Strength Index (RSI) 69.32 53.18
Support Level $15.16 $11.55
Resistance Level $19.21 $14.02
Average True Range (ATR) 0.79 0.93
MACD 0.20 0.12
Stochastic Oscillator 91.13 71.68

Price Performance

Historical Comparison
ALKT
NTLA

About ALKT Alkami Technology Inc.

Alkami Technology Inc is a cloud-based digital banking solutions provider. The company offers the Alkami Digital Sales & Service Platform, which includes a digital banking platform, onboarding and account opening solutions, and data and marketing tools. The platform enables financial institutions to onboard and engage users, support revenue growth, and improve operational efficiency through a cloud-based, multi-tenant architecture. The company provides services to clients under software-as-a-service arrangements. It derives substantially all of its revenues from SaaS subscription services charged for the use of digital sales and service solutions.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: